Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-06-06

Last Posted Date: 2022-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 302

Registration Number: NCT00061945

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: methotrexate
Drug: ifosfamide
Drug: vincristine sulfate

First Posted Date: 2003-05-21

Last Posted Date: 2013-08-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 83

Registration Number: NCT00005977

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Oncology P.A., Dallas, Texas, United States

and more 116 locations

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-05-07

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 41

Registration Number: NCT00005793

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-04-30

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 2000

Registration Number: NCT00003436

Locations: 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cytarabine
Drug: cyclophosphamide
Drug: methotrexate
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate

First Posted Date: 2003-04-25

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00003311

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-04-16

Last Posted Date: 2012-04-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00002945

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-04-11

Last Posted Date: 2013-09-20

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 750

Registration Number: NCT00002701

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹
Federico II University Medical School, Naples (Napoli), Italy
🇮🇹
Ospedale S. Gennora USL 42, Naples (Napoli), Italy

and more 68 locations

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

Phase 3

Conditions: Leukemia
Neutropenia

First Posted Date: 2003-04-10

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 2000

Registration Number: NCT00002658

Locations: 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma
Recurrent Childhood Large Cell Lymphoma
B-cell Childhood Acute Lymphoblastic Leukemia
L3 Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Burkitt Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma

Interventions: Drug: ifosfamide
Drug: etoposide
Biological: rituximab
Drug: carboplatin
Biological: filgrastim
Drug: methotrexate
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT00058461

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: Carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-01

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT00058292

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy